Figure 3.

Pattern of prescribed direct oral anticoagulant dose by eGFR and the FDA recommended dose level. Adding the sample size of cohort of each drug in (A) does not give 3206, the total number of matched direct oral anticoagulant users, because individuals changing from one type to the others were included in two or three different cohorts of each drug. The sample sizes in (B) are slightly smaller than those in (A) due to missing body weight. The current FDA dosing guidelines were applied to all past dosing of each direct oral anticoagulant: Dabigatran 150 mg twice a day and 75 mg twice a day for those with creatinine clearance >30 and creatinine clearance 15–30 ml/min, respectively. Rivaroxaban 20 mg every day and 15 mg every day for those with creatinine clearance >50 and creatinine clearance 15–50 ml/min, respectively. Apixaban 5 mg twice a day unless dose reduction is recommended. Apixaban 2.5 mg twice a day for those with at least two of the following conditions: age≥80 years, body wt ≤60 kg, or serum creatinine ≥1.5 mg/dl. FDA, Food and Drug Administration.